Home / Peptides / Peptides for Anti-Aging

Peptides for Anti-Aging: What GH Secretagogues and NAD+ Can and Can't Do

Higher GH or more fat-free mass does not establish longer life or better function. Evaluate the measured outcome and the costs of the intervention.

M
Written by
B.Sc. (Hons) Chemistry, MBA Pharma Mgmt (Pursuing) · Scientific Content Writer, Strong Health
D
Medically reviewed by
M.D., Board-Certified Psychiatrist · Medical Reviewer, Strong Health
Published: July 16, 2026 Updated: November 17, 2026 · Editorial Standards
5 min read

Key takeaways

  • The MK-677 result concerns an oral non-peptide and one-year endpoints, not a class-wide longevity effect.
  • Increased fat-free mass came without improved strength or function and with metabolic costs.
  • Rat NAD research does not establish benefits of a human supplement or infusion.

Editorially updated November 17, 2026. This revision is awaiting medical review; the reviewer listed above reviewed an earlier version.

An age-related change is not a prescription target by itself

An association between age and a hormone or metabolic marker does not establish that raising the marker improves health. A proposed treatment needs its own evidence for an outcome that matters to the patient.

The cited GH/IGF-1 review discusses longevity findings in mice and uncertainty about how corresponding human biology affects lifespan.[2] It is background research, not a trial showing that a longevity protocol prolongs human life.

What the older-adult MK-677 study measured

The trial enrolled 65 adults aged 60–81 and used a two-year modified-crossover design, with primary endpoints at one year. At 12 months, DXA fat-free mass rose 1.1 kg with MK-677 and fell 0.5 kg with placebo. Strength and function did not improve.[1]

Fasting glucose increased and insulin sensitivity decreased.[1] The body-composition finding must be read with those costs. MK-677 is an oral non-peptide, so its result is not proof of an equivalent effect from CJC-1295, ipamorelin or sermorelin.

Keep NAD biology separate from treatment claims

NAD+ is a coenzyme, not a peptide. A frequently cited 2011 rat NAD study was retracted in 2024. Its reported results should not be used as evidence for a human supplement or infusion. [3]

The NADH guide discusses a related category. A biological relationship between compounds does not make their formulations, routes or treatment effects interchangeable.

Choose a useful outcome instead of a younger-looking lab value

Ask whether the goal is better strength, daily function, relief of a symptom or a body-composition change. Define how the proposed intervention would be evaluated for that goal.

The muscle-growth guide separates tissue measurements from strength. The fatigue guide addresses persistent low energy without assuming it reflects a hormone deficiency.

A repeated biomarker measurement can help describe a response; it does not automatically show that someone is healthier or aging more slowly. The sources summarized here do not establish a lifespan benefit from the marketed protocols.

A combination needs evidence beyond separate mechanisms

Pairing a GH-related intervention with a NAD product or testosterone creates a new treatment question. Separate studies cannot establish the combination's benefit, tolerability or value.

Before paying for a course, ask what diagnosis is being treated, what comparison supports the product, what monitoring is relevant and what would make the clinician stop. A calendar-based protocol is not evidence of effectiveness.

Retain uncertainty and metabolic costs

The MK-677 trial's glucose findings make it inappropriate to describe the category as generally well tolerated without discussing the actual intervention and patient.[1]

Do not translate a research marker into a universal hormone-screening checklist or a dosing schedule. Eligibility, contraindications and monitoring need product-specific assessment.

The belly-fat guide illustrates why a narrow approved indication cannot be repackaged as general longevity evidence. A consultation should clarify those boundaries, not promise reversal of aging.

Frequently Asked Questions

Does a higher GH level prove slower aging?
No. The biomarker and the clinical outcome are different questions. The sources here do not establish that raising GH extends human lifespan.
Was the 1.1 kg result a two-year endpoint?
The highlighted DXA result was measured at 12 months. The overall trial had a two-year modified-crossover design.
Does rat NAD research validate a human protocol?
No. The species, product, route and clinical outcome need relevant human evidence.
Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Authorship and review information are shown where recorded; an editorial update is not a new medical review.

Related Articles

Molecules in this guide

Browse the molecule library →

Compare the research, safety questions and regulatory context for each molecule. Inclusion in this guide does not establish effectiveness or treatment availability.

Looking for care? View Strong Health locations and visit options.

Questions About the Evidence?

Discuss the specific concern, existing care and evidence for any proposed product with a qualified clinician. This guide does not establish treatment availability.

References & Citations

  1. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008.
  2. Junnila RK, et al. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013;9:366–376.
  3. PLOS ONE Editors. Retraction: Age Related Changes in NAD+ Metabolism Oxidative Stress and Sirt1 Activity in Wistar Rats. PLoS One. 2024;19:e0313921.
👉 Book a Free Peptide Therapy Assessment